|1.||Jones, Robert L: 2 articles (09/2003 - 10/2002)|
|2.||Kan, Kelvin K W: 2 articles (09/2003 - 10/2002)|
|3.||Rudd, John A: 2 articles (09/2003 - 10/2002)|
|4.||Gryglewski, Ryszard J: 1 article (01/2008)|
|5.||Yamada, Takehiro: 1 article (07/2005)|
|6.||Yuhki, Koh-ichi: 1 article (07/2005)|
|7.||Karibe, Hideji: 1 article (07/2005)|
|8.||Ma, Hong: 1 article (07/2005)|
|9.||Okada, Yuji: 1 article (07/2005)|
|10.||Fujino, Takayuki: 1 article (07/2005)|
|1.||Neoplasm Metastasis (Metastasis)
07/17/1995 - "Using different treatment schedules, a pronounced reduction of the number of lung metastases was achieved by administration of cicaprost until the end of the experiment (from day 5 to day 35), whereas short-term treatments (from day 5 to day 15 or to day 25) were without significant effect. "
01/01/1994 - "In conclusion, in addition to its dose-dependent effect on haematogenous metastasis, Cicaprost strongly inhibits lymph node metastasis."
01/01/1994 - "Moreover, metastasis to the contralateral axillary lymph node was completely inhibited by Cicaprost at all three doses tested. "
01/01/1994 - "Whereas the median number of lung metastases in the controls was greater than 1000, Cicaprost at a dose of 0.1 mg/kg reduced the number of lung metastases to between 11 and 100. "
01/01/1994 - "Cicaprost given in daily doses of 0.01, 0.03 and 0.1 mg/kg orally, reduced the number of lung metastases in a dose-dependent manner. "
01/01/1997 - "Whereas starting treatment with Cicaprost on the day of tumor implantation was a characteristic feature of our previous investigations, the present study focused on the antimetastatic potency of Cicaprost in animals with established tumor growth. "
01/01/1996 - "As primary tumor growth in vivo or proliferation in vitro remained unchanged by cicaprost, its mode of action seems to be related to one or more mechanisms of the metastatic process. "
07/17/1995 - "Results also indicate that direct effects on tumor cells may contribute to the anti-metastatic action of cicaprost in spontaneously metastasizing tumors."
07/17/1995 - "In addition to its inhibitory potential in animals with advanced tumor disease, cicaprost showed anti-metastatic action when used in peri-operative treatment of animals whose primary tumors had been removed. "
07/17/1995 - "Start of treatment with cicaprost immediately before tumor implantation was a characteristic feature of our previous investigations. "
|3.||Systemic Scleroderma (Systemic Sclerosis)
01/01/1993 - "In this pilot study, we investigated the clinical efficacy of and patient tolerance to two dosage levels of cicaprost (2.5 micrograms tds and 5 micrograms tds) in the treatment of Raynaud's phenomenon secondary to systemic sclerosis (SSc). "
05/01/1991 - "The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study."
01/01/1993 - "A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis."
05/01/1991 - "We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. "
10/01/1993 - "Antiatherosclerotic effects of oral cicaprost in experimental hypercholesterolemia in rabbits."
01/01/1992 - "Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia."
01/01/1992 - "Oral cicaprost resulted in a significantly reduced aortic atheromatous plaque formation and partially prevented hypercholesterolemia-induced impairment of endothelium-dependent relaxations. "
10/01/1993 - "The efficacy of the oral prostacyclin mimetic cicaprost in preventing atheromatous plaque formation was studied in an in vivo model of experimental hypercholesterolemia. "
01/01/1992 - "Cicaprost treatment (5 micrograms/kg x d) largely prevented the hypercholesterolemia-related impairment of coronary vasodilation and nitric oxide release. "
04/01/1998 - "Very similar to our previous investigations in the 13762NF MTLn3 rat mammary carcinoma model, cicaprost administered by i.g. "
01/01/1992 - "The growth of the primary tumour was not influenced by cicaprost in the R 3327 MAT Lu prostate carcinoma nor in the SMT 2A mammary carcinoma in the dose range tested. "
01/01/1992 - "implanted SMT 2A mammary carcinomas, spontaneously metastasizing into regional lymph nodes and lungs, cicaprost (0.1, 0.5 and 1 mg/kg) p.o. "
01/01/1992 - "In Cop rats bearing spontaneously metastasizing R 3327 MAT Lu prostate carcinomas, cicaprost (1.0 mg/kg p.o. "
11/01/1991 - "In Cop-Fisher rats bearing s.c.-implanted spontaneously metastasizing R3327 MAT Lu prostate carcinoma, Cicaprost in a dose of 1.0 mg/kg p.o. "
|4.||Aspirin (Acetylsalicylic Acid)
|8.||Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)